News

Givlaari Effective at Diminishing AHP Symptom Burden: Study

Givlaari (givosiran) can effectively control symptoms of acute hepatic porphyria (AHP), reducing disease burden, even in patients with low attack rates. That’s according to a post hoc analysis of the Phase 3 ENVISION trial (NCT03338816). As noted by researchers, these results support the long-term benefits of Givlaari…

Algorithms Developed to Aid Acute, Cutaneous Porphyria Diagnosis

Two new algorithms that can accurately diagnose acute and cutaneous porphyria have been developed and validated, a study from Belgium reports. According to study’s authors, these algorithms can be used to help clinicians correctly interpret porphyria-related lab tests. “To our knowledge, this is the first time that diagnostic algorithms…

Phase 2 Study to Test Bitopertin for 2 Types of Cutaneous Porphyrias

Disc Medicine has launched a Phase 2 trial of bitopertin, an investigational oral treatment for erythropoietic porphyrias. Dubbed BEACON, the open-label trial will investigate the safety, tolerability, and efficacy of  multiple doses of bitopertin in about 20 patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) at sites…

‘Urgent’ Need in China to Better Diagnose AIP, Study Says

A large proportion of people with acute intermittent porphyria (AIP) may still be undiagnosed in China, according to a recent study — and without a proper diagnosis, they’re not receiving needed treatment, researchers say. “More nationwide epidemiological surveys and study of the prevalence rate of AIP patients in China are…